CN1089249C - 生物适合的生长激素溶液 - Google Patents
生物适合的生长激素溶液 Download PDFInfo
- Publication number
- CN1089249C CN1089249C CN93104030A CN93104030A CN1089249C CN 1089249 C CN1089249 C CN 1089249C CN 93104030 A CN93104030 A CN 93104030A CN 93104030 A CN93104030 A CN 93104030A CN 1089249 C CN1089249 C CN 1089249C
- Authority
- CN
- China
- Prior art keywords
- growth hormone
- solution
- diluent
- concentration
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 145
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 145
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 239000000872 buffer Substances 0.000 claims abstract description 53
- 239000003085 diluting agent Substances 0.000 claims abstract description 53
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 33
- 238000004108 freeze drying Methods 0.000 claims abstract description 31
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000122 growth hormone Substances 0.000 claims description 103
- 239000000243 solution Substances 0.000 claims description 94
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 239000012190 activator Substances 0.000 claims description 17
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical group Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 16
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 16
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 16
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 101000868144 Sus scrofa Somatotropin Proteins 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 230000010358 mechanical oscillation Effects 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- 239000000155 melt Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 4
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical group CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims 1
- 244000125380 Terminalia tomentosa Species 0.000 claims 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims 1
- 239000006174 pH buffer Substances 0.000 claims 1
- 239000004475 Arginine Substances 0.000 abstract description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 4
- 238000013019 agitation Methods 0.000 abstract description 2
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960003121 arginine Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910052723 transition metal Inorganic materials 0.000 description 3
- -1 transition metal salt Chemical class 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 229930192334 Auxin Natural products 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 102000015731 Peptide Hormones Human genes 0.000 description 2
- 108010038988 Peptide Hormones Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000002363 auxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- OWVNHBRJANEEKY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;hydrochloride Chemical compound Cl.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OWVNHBRJANEEKY-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86476892A | 1992-04-07 | 1992-04-07 | |
| US864,768 | 1992-04-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1078910A CN1078910A (zh) | 1993-12-01 |
| CN1089249C true CN1089249C (zh) | 2002-08-21 |
Family
ID=25344034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93104030A Expired - Fee Related CN1089249C (zh) | 1992-04-07 | 1993-04-06 | 生物适合的生长激素溶液 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0639984A1 (fr) |
| JP (1) | JPH08502021A (fr) |
| CN (1) | CN1089249C (fr) |
| AU (1) | AU4278393A (fr) |
| CA (1) | CA2133737A1 (fr) |
| WO (1) | WO1993019773A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751769A (zh) * | 2013-12-25 | 2014-04-30 | 楼秀余 | 一种冻干重组人生长激素胶囊及其制备方法 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5898030A (en) * | 1994-06-17 | 1999-04-27 | Applied Research Systems Ars Holding N.V | hGH containing pharmaceutical compositions |
| KR100236393B1 (ko) * | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| KR20090007504A (ko) | 2000-02-24 | 2009-01-16 | 몬산토 테크놀로지 엘엘씨 | 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들 |
| WO2002000261A2 (fr) | 2000-06-26 | 2002-01-03 | Monsanto Technology Llc | Formulations contenant des tensio-actifs non aqueux permettant une liberation prolongee de somatropine |
| US6664234B1 (en) | 2000-06-30 | 2003-12-16 | Monsanto Technology Llc | Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin |
| CN102753573A (zh) | 2009-12-21 | 2012-10-24 | Ambrx公司 | 经过修饰的牛促生长素多肽和其用途 |
| NZ600363A (en) | 2009-12-21 | 2014-07-25 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
| CN107693486A (zh) | 2012-06-05 | 2018-02-16 | 纽罗德姆有限公司 | 包含阿朴吗啡和有机酸的组合物及其用途 |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| GB201602880D0 (en) | 2016-02-18 | 2016-04-06 | Ge Healthcare Uk Ltd | Method and composition for biomolecule stabilization |
| CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0303746A1 (fr) * | 1987-08-21 | 1989-02-22 | Mallinckrodt Group Inc. | Stabilisation des hormones de croissance |
| WO1990002560A1 (fr) * | 1988-09-12 | 1990-03-22 | Pitman-Moore, Inc. | Promotion de la croissance porcine |
| WO1990014100A2 (fr) * | 1989-05-15 | 1990-11-29 | Pitman-Moore, Inc. | Somatotropine pour accroitre la fertilite chez les animaux |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3325223A1 (de) * | 1983-07-13 | 1985-01-24 | Hoechst Ag, 6230 Frankfurt | Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
-
1993
- 1993-04-05 JP JP5517756A patent/JPH08502021A/ja active Pending
- 1993-04-05 EP EP93912120A patent/EP0639984A1/fr not_active Withdrawn
- 1993-04-05 AU AU42783/93A patent/AU4278393A/en not_active Abandoned
- 1993-04-05 CA CA002133737A patent/CA2133737A1/fr not_active Abandoned
- 1993-04-05 WO PCT/US1993/003182 patent/WO1993019773A1/fr not_active Application Discontinuation
- 1993-04-06 CN CN93104030A patent/CN1089249C/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0303746A1 (fr) * | 1987-08-21 | 1989-02-22 | Mallinckrodt Group Inc. | Stabilisation des hormones de croissance |
| WO1990002560A1 (fr) * | 1988-09-12 | 1990-03-22 | Pitman-Moore, Inc. | Promotion de la croissance porcine |
| WO1990014100A2 (fr) * | 1989-05-15 | 1990-11-29 | Pitman-Moore, Inc. | Somatotropine pour accroitre la fertilite chez les animaux |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751769A (zh) * | 2013-12-25 | 2014-04-30 | 楼秀余 | 一种冻干重组人生长激素胶囊及其制备方法 |
| CN103751769B (zh) * | 2013-12-25 | 2015-08-19 | 楼秀余 | 一种冻干重组人生长激素胶囊及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4278393A (en) | 1993-11-08 |
| CN1078910A (zh) | 1993-12-01 |
| CA2133737A1 (fr) | 1993-10-14 |
| EP0639984A1 (fr) | 1995-03-01 |
| WO1993019773A1 (fr) | 1993-10-14 |
| JPH08502021A (ja) | 1996-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1089249C (zh) | 生物适合的生长激素溶液 | |
| DE60024268T2 (de) | Zusammensetzungen mit stabilem faktor viii | |
| SU1595330A3 (ru) | Композици дл стимул ции лактации у коров и повышени степени усво емости кормов | |
| US4885164A (en) | Aqueous protein solutions stable to denaturation | |
| US4783441A (en) | Aqueous protein solutions stable to denaturation | |
| Brange et al. | Toward understanding insulin fibrillation | |
| EP0618807B1 (fr) | Formulation pharmaceutique stabilisee comportant une somatotrophine et de l'histidine | |
| AU608584B2 (en) | Stable interferon complexes | |
| JP3935938B2 (ja) | ▲ｉｉ▼型コラーゲンの調製法 | |
| US4959351A (en) | Crystal suspensions of insulin derivatives, processes for their preparation and their use | |
| US4637834A (en) | Aqueous protein solutions which are stable towards denaturing, processes for their preparation and their use | |
| CZ297682B6 (cs) | Vodný inzulinový prípravek a zpusob jeho prípravy | |
| JP2016020395A (ja) | ｈＧＨとｒｈＩＧＦ−１の組合せのための配合物 | |
| CN1367703A (zh) | Hgf冻干制剂 | |
| US8148331B2 (en) | Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof | |
| Okubo et al. | Effect of hyperbaric oxygenation on bone induced by recombinant human bone morphogenetic protein-2 | |
| CA2558985C (fr) | Formulation liquide d'erythropoietine | |
| JP4865728B2 (ja) | ポリペプチドの三硫化物誘導体の形成を防止する方法 | |
| JPS62292796A (ja) | 生物学的に不活性な形態のものから活性タンパク質を取得する方法 | |
| JPS6059000A (ja) | インタ−フェロンの安定化方法 | |
| CN88100645A (zh) | 从稀水溶液中回收促生长素的方法 | |
| EP1239894B1 (fr) | Produit pour generer des os | |
| Přistoupil et al. | On the hydrodynamic instability of hemoglobin solutions | |
| RU2261108C2 (ru) | Способ получения комбинированного препарата инсулина человека | |
| Lafeber | Comparison of PTH and hypocalcin in mammalian and teleost bioassays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |